

# Rajeev Vibhakar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5243272/publications.pdf>

Version: 2024-02-01

139  
papers

5,924  
citations

116194

36  
h-index

87275

74  
g-index

144  
all docs

144  
docs citations

144  
times ranked

8982  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	7.7	836
2	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761
3	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
4	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
5	Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2008, 90, 1-7.	1.4	230
6	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	3.9	169
7	MicroRNA 128a Increases Intracellular ROS Level by Targeting Bmi-1 and Inhibits Medulloblastoma Cancer Cell Growth by Promoting Senescence. <i>PLoS ONE</i> , 2010, 5, e10748.	1.1	158
8	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
9	Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 6665-6674.	0.4	135
10	Activation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes. <i>Experimental Cell Research</i> , 1997, 232, 25-28.	1.2	133
11	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	13.7	129
12	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. <i>ELife</i> , 2017, 6, .	2.8	128
13	Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. <i>Neuro-Oncology</i> , 2013, 15, 149-160.	0.6	115
14	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. <i>Oncotarget</i> , 2014, 5, 2355-2371.	0.8	103
15	B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2013, 111, 257-264.	1.4	101
16	MicroRNA 218 Acts as a Tumor Suppressor by Targeting Multiple Cancer Phenotype-associated Genes in Medulloblastoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 1918-1928.	1.6	100
17	The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. <i>Gene</i> , 1997, 197, 177-187.	1.0	99
18	Survey of MicroRNA expression in pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2011, 56, 211-216.	0.8	89

#	ARTICLE	IF	CITATIONS
19	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. <i>Nature Communications</i> , 2019, 10, 5829.	5.8	77
20	Targeting the enhancer of zeste homologue 2 in medulloblastoma. <i>International Journal of Cancer</i> , 2012, 131, 1800-1809.	2.3	71
21	Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. <i>BMC Cancer</i> , 2012, 12, 80.	1.1	69
22	Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma. <i>Neuro-Oncology</i> , 2007, 9, 135-144.	0.6	64
23	Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. <i>Molecular Cancer</i> , 2014, 13, 72.	7.9	62
24	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. <i>Cancer Immunology Research</i> , 2015, 3, 1165-1174.	1.6	61
25	A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2058-2068.	1.9	61
26	Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. <i>Journal of Neuro-Oncology</i> , 2013, 111, 113-121.	1.4	59
27	Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. <i>Journal of Neuro-Oncology</i> , 2012, 107, 517-526.	1.4	56
28	High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. <i>Neuro-Oncology</i> , 2011, 13, 1296-1307.	0.6	52
29	Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, 273-286.	0.6	52
30	Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. <i>Neuro-Oncology</i> , 2012, 14, 175-183.	0.6	51
31	Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. <i>Oncotarget</i> , 2018, 9, 13894-13910.	0.8	47
32	Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and Etiology. <i>Cell Reports</i> , 2020, 32, 108023.	2.9	47
33	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	5.8	47
34	Fractionated stereotactic radiosurgery for recurrent ependymoma in children. <i>Journal of Neuro-Oncology</i> , 2014, 116, 107-111.	1.4	45
35	Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. <i>International Journal of Cancer</i> , 2019, 144, 1983-1995.	2.3	43
36	A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. <i>ACS Chemical Biology</i> , 2016, 11, 921-930.	1.6	42

#	ARTICLE	IF	CITATIONS
37	Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1095-1102.	0.8	40
38	Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines. <i>Pediatric Blood and Cancer</i> , 2010, 55, 35-41.	0.8	39
39	Aurora kinase A as a rational target for therapy in glioblastoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 6, 98-105.	0.8	39
40	Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. <i>Cell Reports</i> , 2020, 33, 108286.	2.9	39
41	MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3). <i>Brain Pathology</i> , 2020, 30, 732-745.	2.1	35
42	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
43	Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28028.	0.8	33
44	NF- $\kappa$ B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. <i>Neuro-Oncology</i> , 2017, 19, 1350-1360.	0.6	32
45	Polo-like Kinase-1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. <i>BMC Cancer</i> , 2016, 16, 647.	1.1	31
46	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. <i>Oncogene</i> , 2020, 39, 2305-2327.	2.6	31
47	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. <i>Nature Communications</i> , 2021, 12, 5531.	5.8	31
48	Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1158.	1.0	30
49	Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma. <i>Cell Reports</i> , 2020, 31, 107485.	2.9	27
50	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 944-954.	0.6	25
51	Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. <i>Cell Death and Disease</i> , 2019, 10, 679.	2.7	24
52	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	3.3	24
53	MPS1 kinase as a potential therapeutic target in medulloblastoma. <i>Oncology Reports</i> , 2016, 36, 2633-2640.	1.2	23
54	The long noncoding RNA <i>lnc-HLX-2-7</i> is oncogenic in Group 3 medulloblastomas. <i>Neuro-Oncology</i> , 2021, 23, 572-585.	0.6	23

#	ARTICLE	IF	CITATIONS
55	Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma. JCI Insight, 2019, 4, .	2.3	20
56	Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncology Reports, 2018, 39, 455-464.	1.2	19
57	Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood. Journal of Neuropathology and Experimental Neurology, 2017, 76, 595-604.	0.9	19
58	Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Molecular Cancer Therapeutics, 2018, 17, 1984-1994.	1.9	19
59	Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. Cell Reports, 2021, 35, 109013.	2.9	18
60	Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget, 2016, 7, 53881-53894.	0.8	17
61	Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma. Cancer Cell International, 2017, 17, 41.	1.8	16
62	Aberrant T-Cell Antigen Receptor-Mediated Responses in Autoimmune Lymphoproliferative Syndrome. Clinical Immunology, 2002, 104, 31-39.	1.4	15
63	Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. Oncotarget, 2017, 8, 97290-97303.	0.8	15
64	A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro-Oncology, 2022, 24, 414-426.	0.6	15
65	Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF- $\kappa$ B Pathway in Preclinical Models of Pediatric High-Grade Glioma. Molecular Cancer Therapeutics, 2020, 19, 540-551.	1.9	14
66	Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia. Frontiers in Oncology, 2020, 10, 296.	1.3	14
67	Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile. Communications Biology, 2021, 4, 616.	2.0	13
68	Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors. Pediatric Blood and Cancer, 2014, 61, 120-127.	0.8	12
69	Tumor treating fields in pediatric high-grade glioma. Child's Nervous System, 2017, 33, 1043-1045.	0.6	12
70	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	2.7	12
71	Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. Neuro-Oncology, 2019, 21, 1540-1551.	0.6	11
72	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Medicine, 2020, 9, 447-459.	1.3	11

#	ARTICLE	IF	CITATIONS
73	A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma. <i>Cancers</i> , 2021, 13, 387.	1.7	11
74	Preclinical and clinical investigation of intratumoral chemotherapy pharmacokinetics in DIPG using gemcitabine. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa021.	0.4	10
75	Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. <i>Journal of Neuro-Oncology</i> , 2020, 147, 531-545.	1.4	10
76	Bromodomain and extra-terminal inhibitors: A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children: ACCELERATE. <i>European Journal of Cancer</i> , 2021, 146, 115-124.	1.3	10
77	The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme. <i>Molecular Carcinogenesis</i> , 2020, 59, 1064-1075.	1.3	9
78	Therapeutic targeting of immune checkpoints with small molecule inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 529-541.	0.0	9
79	Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels. <i>Blood</i> , 2022, 139, 2240-2251.	0.6	9
80	Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa051.	0.4	8
81	Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26656.	0.8	7
82	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa103.	0.4	6
83	Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth. <i>Clinical Cancer Research</i> , 2022, 28, 2409-2424.	3.2	6
84	NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 345-353.	0.9	5
85	SMYD3 Promotes Cell Cycle Progression by Inducing Cyclin D3 Transcription and Stabilizing the Cyclin D1 Protein in Medulloblastoma. <i>Cancers</i> , 2022, 14, 1673.	1.7	5
86	Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	4
87	MB-71 THE ROLE OF WEE1 IN Myc-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii113.2-iii113.	0.6	2
88	HG-78 SYNTHETIC LETHAL EPIGENETIC INTERACTIONS IN K27M MUTATED DIPG. <i>Neuro-Oncology</i> , 2016, 18, iii66.3-iii66.	0.6	1
89	Vincristine and Vinblastine: Is checking bilirubin mandatory in children with Brain Tumors?. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26329.	0.8	1
90	PHRM-02. DELIVERY OF CHEMOTHERAPEUTICS TO PEDIATRIC BRAIN TUMORS USING CITRATE-CAPPED GOLD NANOPARTICLES. <i>Neuro-Oncology</i> , 2018, 20, i157-i157.	0.6	1

#	ARTICLE	IF	CITATIONS
91	MEDU-13. FUNCTIONAL CRISPR-CAS9 SCREEN IDENTIFIES DRUGGABLE DEPENDENCIES IN MYC-DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii105-ii106.	0.6	1
92	Converging evidence for inhibition of transcriptional control in high-grade gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1225-1227.	0.6	1
93	Epigenetic Regulation of Von Willebrand Factor Gene Expression May Contribute to Von Willebrand Disease Severity. <i>Blood</i> , 2014, 124, 470-470.	0.6	1
94	EP-04 * ACTIVATION OF THE IL6/STAT3 PATHWAY IN CHILDHOOD EPENDYMOMA IS ASSOCIATED WITH A PRO-INFLAMMATORY TUMOR MICROENVIRONMENT AND A POOR PROGNOSIS. <i>Neuro-Oncology</i> , 2015, 17, iii6-iii6.	0.6	0
95	AT-07PLK1 AS A THERAPEUTIC TARGET IN ATRT. <i>Neuro-Oncology</i> , 2016, 18, iii2.2-iii2.	0.6	0
96	EPEN-21. SINGLE CELL RNASEQ IDENTIFIES A PUTATIVE CANCER STEM CELL POPULATION IN POSTERIOR FOSSA EPN. <i>Neuro-Oncology</i> , 2018, 20, i77-i77.	0.6	0
97	DIPG-66. THE H3K27M MUTATION CAUSES WIDE-RANGING CHANGES MEDIATING DIPG TUMORIGENESIS. <i>Neuro-Oncology</i> , 2018, 20, i62-i62.	0.6	0
98	DIPG-77. INTRATUMORAL PHARMACOKINETICS OF CHEMOTHERAPY IN DIPG: XENOGRAFT AND INITIAL PHASE 0 CLINICAL TRIAL RESULTS. <i>Neuro-Oncology</i> , 2018, 20, i64-i65.	0.6	0
99	QOL-58. IMPROVEMENT IN VISUAL ACUITY OF PEDIATRIC PATIENTS WITH BRAIN TUMORS WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, i169-i169.	0.6	0
100	ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i31-i31.	0.6	0
101	MBRS-23. EFFECT OF KNOCKDOWN OF KDM6A BY CRISPR/CAS9 EDITING IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i133-i133.	0.6	0
102	EPEN-16. PATIENT-DERIVED PFA EPENDYMOMA XENOGRAFT MODEL. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	0.6	0
103	DIPG-10. THE ONCOGENIC ROLE OF THE SUPER ELONGATION COMPLEX IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i50-i50.	0.6	0
104	HGG-45. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF PEDIATRIC TREATMENT-INDUCED HIGH-GRADE GLIOMA: GERMLINE DNA REPAIR DEFECTS AS A POTENTIAL ETIOLOGY. <i>Neuro-Oncology</i> , 2018, 20, i98-i98.	0.6	0
105	PDTM-41. SUPER ELONGATION COMPLEX-MEDIATED TRANSCRIPTIONAL DEPENDENCY IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi212-vi212.	0.6	0
106	EPEN-14. SUBGROUP-SPECIFIC THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	0.6	0
107	MBRS-22. EZH2 OVEREXPRESSION INCREASES THE ONCOGENIC CHARACTER OF CEREBELLAR PROGENITORS AND ISOGRAFTS IN MICE RESULT IN TUMORS RESEMBLING GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i132-i133.	0.6	0
108	EPEN-15. RETINOIDS AS POTENTIAL CHEMOTHERAPEUTIC OPTIONS FOR POSTERIOR FOSSA EPENDYMOMA OF CHILDHOOD. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	0.6	0



#	ARTICLE	IF	CITATIONS
109	MEDU-19. EZH2-REGULATED INHIBITION OF HIPK2 SUPPRESSES TREATMENT-INDUCED APOPTOSIS IN GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii107-ii107.	0.6	0
110	DIPG-07. EPIGENOME SCREENING IDENTIFIES TRANSCRIPTIONAL ELONGATION AS THERAPEUTIC VULNERABILITY IN H3K27M-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii69-ii69.	0.6	0
111	DIPG-28. NTRK FUSIONS IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii74-ii75.	0.6	0
112	EPEN-09. PRECLINICAL MODELS REVEAL SUBGROUP-STRATIFIED TARGETED THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2019, 21, ii79-ii79.	0.6	0
113	ATRT-05. PRC1 IS AN ESSENTIAL DEPENDENCY AND THERAPEUTIC TARGET IN SMARCB1 DEFICIENT ATYPICAL TERATOID RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2019, 21, ii63-ii64.	0.6	0
114	EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, i11-i12.	0.6	0
115	RARE-18. NF1-MUTATED TUMORS EXHIBIT INCREASED SENSITIVITY TO AUTOPHAGY INHIBITION ALONE AND IN COMBINATION WITH MEK INHIBITION. <i>Neuro-Oncology</i> , 2021, 23, i44-i44.	0.6	0
116	EMBR-30. A NOVEL PLK1 INHIBITOR ONVANSERTIB EFFECTIVELY SENSITIZES GROUP 3 MEDULLOBLASTOMA TO RADIOTHERAPY. <i>Neuro-Oncology</i> , 2021, 23, i12-i12.	0.6	0
117	HGG-25. PRMT5 PROMOTES TUMOR GROWTH BY MAINTAINING STEMNESS OF PEDIATRIC HIGH-GRADE GLIOMA CELLS. <i>Neuro-Oncology</i> , 2021, 23, i22-i22.	0.6	0
118	HGG-29. VENETOCLAX SYNERGIZES WITH RADIATION THERAPY FOR THE TREATMENT OF DIPG. <i>Neuro-Oncology</i> , 2021, 23, i23-i23.	0.6	0
119	Successful Unrelated Umbilical Cord Blood Transplantation for Shwachman-Diamond Syndrome.. <i>Blood</i> , 2004, 104, 5179-5179.	0.6	0
120	MBRS-26. CDK7 MEDIATED TRANSCRIPTIONAL PROCESSIVITY OF DNA REPAIR NETWORKS REGULATES SENSITIVITY TO RADIATION IN MYC DRIVEN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii403-iii403.	0.6	0
121	MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq. <i>Neuro-Oncology</i> , 2020, 22, iii406-iii406.	0.6	0
122	ATRT-24. CELL SURFACE PROTEOME ANALYSIS OF ATRT IDENTIFIES TARGETS FOR IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, iii280-iii280.	0.6	0
123	ATRT-20. CDK7 INHIBITION IN AT/RT. <i>Neuro-Oncology</i> , 2020, 22, iii279-iii280.	0.6	0
124	EPEN-31. SINGLE-CELL RNAseq OF CHILDHOOD EPENDYMOMA REVEALS DISTINCT NEOPLASTIC CELL SUBPOPULATIONS THAT IMPACT ETIOLOGY, MOLECULAR CLASSIFICATION AND OUTCOME. <i>Neuro-Oncology</i> , 2020, 22, iii314-iii314.	0.6	0
125	IMG-17. RADIOMICS CHARACTERIZATION OF FOUR PEDIATRIC BRAIN TUMOR SUBTYPES IN PDX MOUSE MODELS. <i>Neuro-Oncology</i> , 2020, 22, iii358-iii358.	0.6	0
126	MBRS-65. FBXW7 ACTS A TUMOR SUPPRESSOR IN MYC-DRIVEN MEDULLOBLASTOMA BY CONTROLLING A FEED-FORWARD REGULATORY LOOP OF PLK1 AND MYC. <i>Neuro-Oncology</i> , 2020, 22, iii409-iii409.	0.6	0



#	ARTICLE	IF	CITATIONS
127	ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT). <i>Neuro-Oncology</i> , 2020, 22, iii276-iii277.	0.6	0
128	ATRT-23. SIRT2 cooperates with SMARCB1 to induce a differentiation block in ATRT. <i>Neuro-Oncology</i> , 2022, 24, i8-i8.	0.6	0
129	HGG-20. PRMT5 promotes the formation and growth of pediatric high-grade glioma by maintaining tumor stem cell populations. <i>Neuro-Oncology</i> , 2022, 24, i64-i65.	0.6	0
130	DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma. <i>Neuro-Oncology</i> , 2022, 24, i31-i31.	0.6	0
131	MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i125-i125.	0.6	0
132	IMMU-23. Novel gene-edited CAR-T cell therapy against Diffuse Intrinsic Pontine Glioma. <i>Neuro-Oncology</i> , 2022, 24, i86-i87.	0.6	0
133	RONC-05. Peri-transplant Radiation Therapy for Young Children Treated with High-Dose Chemotherapy for Primary Brain Tumors. <i>Neuro-Oncology</i> , 2022, 24, i177-i177.	0.6	0
134	MEDB-70. Metabolism mediated radiation resistance in MYC-driven Medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i122-i123.	0.6	0
135	IMMU-21. Targeting the adenosinergic immune suppression pathway in high grade glioma synergizes with innate immune checkpoint blockade. <i>Neuro-Oncology</i> , 2022, 24, i86-i86.	0.6	0
136	ATRT-10. Single-cell transcriptional profiling of ATRTs reveals heterogeneous signatures of tumor and non-malignant cell populations. <i>Neuro-Oncology</i> , 2022, 24, i4-i5.	0.6	0
137	MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i125-i125.	0.6	0
138	DIPG-61. Preclinical efficacy of combined radiotherapy with venetoclax treatment in targeting diffuse midline gliomas. <i>Neuro-Oncology</i> , 2022, 24, i32-i33.	0.6	0
139	MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture. <i>Neuro-Oncology</i> , 2022, 24, i115-i116.	0.6	0